Publications + Posters

 |  Organic Process Research & Development

February 2025

Development of a Commercial Ready Process for TNG908: A Potent, Selective, and Brain-Penetrant MTA-Cooperative PRMT5 Inhibitor

Colin Liang, et al.

 |  Translational Oncology

January 2025

TNG908 is a brain-penetrant, MTA-cooperative PRMT5 inhibitor developed for the treatment of MTAP-deleted cancers

Kimberly J. Briggs, et al.

 |  SLAS Technology

July 2024

A duplexed high-throughput mass spectrometry assay for bifunctional POLB polymerase and lyase activity

Zachary A. Gurard-Levin, et al.

 |  ACS National Medicinal Chemistry Symposium

June 2024

MTA-cooperative PRMT5 inhibitors: mechanism switching through structure-based design

Kevin M. Cottrell, et al.

 |  Journal of Medicinal Chemistry

April 2024

Discovery of TNG908: A selective, brain penetrant, MTA-cooperative PRMT5 inhibitor that is synthetically lethal with MTAP-deleted cancers

Kevin M. Cottrell, et al.